NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
04/06/2026
Voltar para busca
Dado oficial do USPTO
LAMBDA-CAP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LAMBDA-CAP
ST13
US500000079250615Classe
1, 5, 42
Pedido
79250615
Registro
5980170
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
23/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
03/12/2018
Data de registro
11/02/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/06/2026
Última transação
23/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
Wädenswil, CH
Examinador
MARTINS, ODETTE
Localização atual
Historical data usage
Titulares e representantes
Titulares
Numab Therapeutics AG
Numab Therapeutics AG
Representantes
Dennis S. Prahl Ladas & Parry LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemicalbiological and biotechnological products intended for industry and sciencebiological preparations for use in industry and sciencediagnostic preparations for clinical and medical laboratory use; chemicalbiochemicalbiological and biotechnological productsantibodies and antibody particles for development and manufacture of pharmaceutical products; biological productsantibodies and antibody fragments for use in laboratoriesdiagnosis and analysis for scientific and research purposes; chemical and biochemical additivessupports and substances for the manufacture of pharmaceutical products
Classe 5
Pharmaceutical and veterinary productspharmaceutical products for the prevention and treatment of immune system related diseases and disorderstherapeutic vaccines; pharmaceutical preparationspharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; medicines for human medicinemedicinal preparations for the treatment of infectious diseases and for use in oncology; chemical pharmaceutical products for the diagnosis and treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; diagnostic preparations for medical use; chemical preparations for pharmaceutical use namelyfor diagnosing and treating cancerleukemialymphomasinflammatory diseasesimmunological diseases
Classe 42
Research and development in the field of pharmaceutical productsbiotechnologyantibodies and antibody fragmentsproteinsmicro-organisms and cells for therapeutic purposes; research with respect to pharmaceutical productsbiotechnologytherapyantibody and gene therapy; researchproduct development and quality control in the field of pharmacydiagnostics and therapy; research in the field of chemistry and biology; industrial analysis and research services in the field of biochemistry and pharmaceuticals; research and development of antibody products for therapeutic purposes; preparing and conducting chemicalbiochemical and biotechnological analysis and research
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
04/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/06/2026
ES75
TEAS SECTION 71 & 15 RECEIVED
05/02/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/02/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
31/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/08/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
20/08/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/06/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
27/05/2020
FIMP
FINAL DISPOSITION PROCESSED
27/05/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
11/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/11/2019
PUBO
PUBLISHED FOR OPPOSITION
26/11/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/11/2019
ALIE
ASSIGNED TO LIE
21/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/10/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
10/10/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/10/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
10/10/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
21/06/2019
RFNT
REFUSAL PROCESSED BY IB
05/04/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/03/2019
RFRR
REFUSAL PROCESSED BY MPU
20/03/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/03/2019
CNRT
NON-FINAL ACTION WRITTEN
12/03/2019
DOCK
ASSIGNED TO EXAMINER
03/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
09/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/02/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
31/01/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LAMBDA-CAP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.